Read Gene

Read Gene Financial Debt Ratio

The Financial Debt Ratio of Read Gene (RDG.WA) as of Nov 6, 2026 is 54.41 %. In the previous year, Financial Debt Ratio was 53.85 % — a change of 1.04% (higher).

Financial Debt Ratio

54.41 %

YoY

1.04%

Last updated:

Financial Debt Ratio of Read Gene is 2025 54.41 % . Financial Debt Ratio of Read Gene was 2024 53.85 % . It decreases by 1.04% higher compared to the previous year.

The Read Gene Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2016
1.46 PLN
Jan 1, 2017
2.44 PLN
Jan 1, 2020
28.97 PLN
Jan 1, 2021
31.58 PLN
Jan 1, 2022
45.10 PLN
Jan 1, 2023
49.68 PLN
Jan 1, 2024
53.85 PLN
Jan 1, 2025
54.41 PLN
The Read Gene Financial Debt Ratio history
YEARFinancial Debt RatioYoY
54.41 %+1.04%
53.85 %+8.41%
49.68 %+10.16%
45.10 %+42.80%
31.58 %+9.03%
28.97 %+1,089.54%
2.44 %+66.34%
1.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Financial Debt Ratio of Read Gene is 54.41 % in 2025.

Financial Debt Ratio of Read Gene changed from 53.85 % to 54.41 %, representing a 1.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Read Gene since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Read Gene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Read Gene

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Read Gene